Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MPO | P05164 | 1/20 | 0.32 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.32 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.32 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28161922 | 0.94 | KMT2A (0.41) | CYP2D6KMT2AKDM4EHSD11B1SMN1; SMN2 | |
| SCHEMBL14694085 | 0.87 | CHKA (0.34) | CYP2D6KMT2AKDM4ECARM1PRMT6 | |
| SCHEMBL48580 | 0.86 | — | — | |
| SCHEMBL1093603 | 0.86 | — | — | |
| SCHEMBL13915449 | 0.86 | CYP2D6 (0.48) | CYP2D6KMT2AKDM4ECARM1PRMT6 | |
| SCHEMBL1043052 | 0.86 | CYP2D6 (0.48) | CYP2D6KMT2AKDM4ECARM1PRMT6 | |
| SCHEMBL575183 | 0.86 | — | — | |
| SCHEMBL8403766 | 0.84 | HRH3 (0.50) | HRH3 | |
| SCHEMBL8640308 | 0.84 | CYP2D6 (0.32) | CYP2D6KMT2A | |
| SCHEMBL8406009 | 0.84 | HRH3 (0.50) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12473405-B2 | Polyorganosiloxane, polyorganosiloxane composition, cured product, polyorganosiloxane-containing electrolytic solution for electrolytic capacitor, and electrolytic capacitor using same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2025-11-18 | — | — | US | disclosed |
| US-20240297344-A1 | NONAQUEOUS ELECTROLYTE FOR SECONDARY BATTERY AND NONAQUEOUS-ELECTROLYTE SECONDARY BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-09-05 | — | — | US | disclosed |
| CN-118159584-A | Curable resin composition and cured product thereof | 株式会社大赛璐 | 2024-06-07 | — | — | CN | disclosed |
| US-20230348658-A1 | COPOLYMERS AND TERPOLYMERS OF POST MODIFIED POLYACRYLATES AS EFFICIENT GAS HYDRATE INHIBITORS | SAUDI ARABIAN OIL COMPANY (SA) | 2023-11-02 | — | — | US | disclosed |
| EP-3232455-B1 | NONAQUEOUS ELECTROLYTE SOLUTION FOR ELECTRIC DOUBLE LAYER CAPACITORS | OTSUKA CHEMICAL CO LTD (JP) | 2023-10-25 | — | — | EP | disclosed |
| US-20230250237-A1 | POLYORGANOSILOXANE, POLYORGANOSILOXANE COMPOSITION, CURED PRODUCT, POLYORGANOSILOXANE-CONTAINING ELECTROLYTIC SOLUTION FOR ELECTROLYTIC CAPACITOR, AND ELECTROLYTIC CAPACITOR USING SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2023-08-10 | — | — | US | disclosed |
| CN-116438066-A | Laminated film and flexible device | 株式会社大赛璐 | 2023-07-14 | — | — | CN | disclosed |
| US-20230203055-A1 | FUSED RING COMPOUND AND APPLICATION THEREOF IN MEDICINE | BETTA PHARMACEUTICALS CO., LTD (CN) | 2023-06-29 | — | — | US | disclosed |
| CN-116018261-A | Polyorganosilsesquioxane, curable composition, cured product, hard coating film, adhesive sheet, and laminate | 株式会社大赛璐 | 2023-04-25 | — | — | CN | disclosed |
| US-11616253-B2 | Nonaqueous electrolyte for secondary battery and nonaqueous-electrolyte secondary battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2023-03-28 | — | — | US | disclosed |
| EP-1564768-A1 | ELECTROLYTE FOR ELECTROLYTIC CAPACITOR, ELECTROLYTIC CAPACITOR AND PROCESS FOR PRODUCING TETRAFLUOROALUMINATE SALT OF ORGANIC ONIUM | Mitsubishi Chemical Corporation (JP) | 2005-08-17 | — | — | EP | disclosed |
| CN-1511327-A | Electrolyte for electrolytic capacitor and electrolytic capacitor using the same | ������ѧ��ʽ���� | 2004-07-07 | — | — | CN | disclosed |
| US-20040095708-A1 | Electrolyte for electolytic capacitor and electrolytic capacitor using the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2004-05-20 | — | — | US | disclosed |
| EP-1394824-A1 | ELECTROLYTIC SOLUTION FOR ELECTROLYTIC CAPACITOR AND ELECTROLYTIC CAPACITOR USING IT | Mitsubishi Chemical Corporation (JP) | 2004-03-03 | — | — | EP | disclosed |
| CN-1465117-A | Nonaqueous electrolyte and secondary battery using the same | MITSUBISHI CHEM CORP (JP) | 2003-12-31 | — | — | CN | disclosed |
| EP-0971877-B1 | PRODUCTION OF 1,3-DIAMINOPENTANE BY HYDROGENATION OF 3-AMINOPENTANENITRILE | DU PONT (US) | 2002-06-12 | — | — | EP | disclosed |
| CN-1251566-A | Production of 1,3-diaminopentane by hydrogenation of 3-aminopentanenitrile | PONT DE NEMOUR AND CO DU (US) | 2000-04-26 | — | — | CN | disclosed |
| EP-0971877-A1 | PRODUCTION OF 1,3-DIAMINOPENTANE BY HYDROGENATION OF 3-AMINOPENTANENITRILE | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2000-01-19 | — | — | EP | disclosed |
| US-5898085-A | Production of 1,3-diaminopentane by hydrogenation of 3-aminopentanenitrile | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1999-04-27 | — | — | US | disclosed |
| WO-1998043941-A1 | PRODUCTION OF 1,3-DIAMINOPENTANE BY HYDROGENATION OF 3-AMINOPENTANENITRILE | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1998-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203055-A1 | FUSED RING COMPOUND AND APPLICATION THEREOF IN MEDICINE | VIP, CYP11B2, CYP11B1 | CYP2D6 123/4885KMT2A 3977/4885KDM4E 3474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.